Maternal Diabetes Driving Congenital Heart Disease Market Growth: Powering Innovation and Expansion in the Global Congenital Heart Disease (CHD) Market by 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Congenital Heart Disease (CHD) Market Through 2025?
The market pertaining to congenital heart disease (chd) has experienced robust expansion recently, projected to increase from $4.42 billion in 2024 to $4.85 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.7%; this past period's upward trend resulted from several factors, including a rise in associated risk elements like obesity and tobacco use, advancements in diagnostic capabilities, a growing elderly demographic, amplified public awareness initiatives, better reimbursement frameworks, and greater financial input into scientific exploration and product development.

What's the Projected Size of the Global Congenital Heart Disease (CHD) Market by 2029?
The market encompassing congenital heart disease is projected to experience robust expansion over the upcoming years, achieving a valuation of $6.82 billion by 2029, driven by an 8.9% compound annual growth rate; this upward trajectory is supported by broader availability of medical care in emerging economies, ongoing technological advancements in cardiac visualization, increasing public understanding fostered by awareness initiatives encouraging prompt diagnosis and intervention, escalating worldwide spending on health services, and advancements in tailoring treatments to individual patient needs. Key directional shifts anticipated during this projection timeframe involve a greater incorporation of surgical methods requiring less invasive procedures, wider application of remote care technologies like telehealth for overseeing patients from afar and conducting virtual appointments, an increasing need for tailor-made treatment strategies, the creation of novel internal medical devices boasting superior performance features and longer operational lifespans, alongside the integration of artificial intelligence and machine learning tools within diagnostic and treatment protocols.

View the full report here:
https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Top Growth Drivers in the Congenital Heart Disease (CHD) Industry: What's Accelerating the Market?
Anticipated escalation in instances of maternal diabetes is projected to be a key catalyst fueling the expansion of the congenital heart disease (CHD) market in the foreseeable future. This condition, known medically as gestational diabetes mellitus (GDM), manifests when diabetes develops during gestation in individuals who were not previously diabetic before becoming pregnant. Contributing factors to maternal diabetes include shifts in lifestyle, such as increasingly sedentary routines and poor nutritional choices, alongside a broader ascent in the prevalence of obesity among women capable of bearing children. A direct consequence of uncontrolled maternal diabetes is the heightened likelihood of a baby developing congenital heart disease, as elevated maternal blood glucose levels interfere with the proper formation of the fetal heart structure. Specifically, excessive glucose circulating in the mother's bloodstream can impede the typical developmental trajectory of the infant's heart, thereby elevating the probability of CHD occurring. Illustratively, data published by the UK's National Health Service in October 2023 indicated that the proportion of adverse pregnancy outcomes for women identified with type 2 diabetes saw a rise from 4.9% in 2021 to 6.6% in 2022. Consequently, the rising tide of maternal diabetes cases stands as a significant driver propelling the growth trajectory of the congenital heart disease (CHD) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

What Trends Will Shape the Congenital Heart Disease (CHD) Market Through 2029 and Beyond?
Leading corporations within the congenital heart disease sector are currently focusing efforts on innovating non-surgical heart valve replacements, aiming to enhance the well-being and overall quality of life for those affected. These transcatheter devices, which circumvent the necessity for conventional invasive cardiac procedures, offer a treatment avenue for valve disorders. As an illustration, in February 2023, Medtronic, a prominent medical technology firm headquartered in the United States, relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System. Representing a significant departure from traditional procedures, this novel, minimally invasive option targets individuals afflicted with congenital heart defects, particularly those presenting with irregularities in the right ventricular outflow tract (RVOT), whether naturally occurring or post-surgical repair. This specific system achieved distinction as the inaugural valve authorized by the FDA intended for right-sided use, thereby furnishing a non-operative remedy for severe pulmonary valve leakage. Although the Harmony TPV System initially gained sanction from the U.S. FDA in 2021, its subsequent reintroduction underscored Medtronic's dedication to progress in managing congenital heart disease, following an earlier voluntary withdrawal from the market.

What Are the Main Segments in the Congenital Heart Disease (CHD) Market?
The congenital heart disease (chd)market covered in this report is segmented -

1) By Type: Heart Valve Defects; Heart Wall Defects; Blood Vessel Defects; Other Types
2) By Diagnosis: Electrocardiogram; Chest X-ray; Echocardiogram; Transesophageal Echocardiogram; Pulse Oximetry; Exercise Stress Test; Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI); Cardiac Catheterization; Other Diagnosis
3) By Treatment: Interventional Cardiology; Cardiac Surgery; Telemedicine; Medication Management; Lifestyle Modifications
4) By Age Group: Infants; Children; Adolescents; Adults
5) By Application: Hospitals And Clinics; Diagnostic Centers; Ambulatory Surgical Centers; Research And Academic Institutions

Subsegments:
1) By Heart Valve Defects: Aortic Valve Stenosis; Pulmonary Valve Stenosis; Mitral Valve Prolapse; Tricuspid Valve Defects; Valve Regurgitation
2) By Heart Wall Defects: Atrial Septal Defect (ASD); Ventricular Septal Defect (VSD); Atrioventricular Septal Defect (AVSD); Hypoplastic Left Heart Syndrome (HLHS); Tetralogy of Fallot (TOF)
3) By Blood Vessel Defects: Coarctation Of The Aorta; Patent Ductus Arteriosus (PDA); Pulmonary Artery Stenosis; Transposition Of The Great Arteries (TGA); Truncus Arteriosus
4) By Other Types: Single Ventricle Defects; Ebstein's Anomaly; Total Anomalous Pulmonary Venous Return (TAPVR); Coronary Artery Anomalies; Pulmonary Venous Obstruction

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15545&type=smp

Which Top Companies are Driving Growth in the Congenital Heart Disease (CHD) Market?
Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd

Which Regions Will Dominate the Congenital Heart Disease (CHD) Market Through 2029?
North America was the largest region in the congenital heart disease (CHD) market in 2024. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15545

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.